US Obesity Rates Show First Decline in Decade, Linked to Surge in GLP-1 Weight-Loss Drugs

The United States has faced a persistent obesity epidemic since the late 1970s, but emerging data suggests that rising obesity rates may finally be reversing. For the first time in over a decade, recent studies indicate a potential decline in adult obesity prevalence.

“We’re seeing signs that there’s going to be a turning point,” said Benjamin Rader, an epidemiologist at Boston Children’s Hospital and Harvard Medical School who analyzes health trends using large datasets. His 2024 study, which examined data from more than 16 million adults, found evidence of declining obesity rates in 2023 — marking the first such reduction in over ten years.

The National Health and Nutrition Examination Survey also reported a slight decrease in obesity rates between 2021 and 2023, with additional surveys supporting these findings.

Use of Ozempic, Wegovy and Zepbound skyrockets

This shift coincides with the rapid expansion of new weight-loss medications. The GLP-1 agonist drugs Ozempic, Wegovy, and Zepbound have seen prescription volumes increase dramatically, more than quadrupling between 2021 and early 2026.

Originally developed to treat Type 2 diabetes, these medications work by mimicking intestinal hormones that promote satiety and slow gastric emptying. Many patients have experienced substantial weight loss as a result.

Weight-loss drugs Wegovy, Ozempic, Mounjaro boom in UK

To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video

Rader noted that the timing of these medications’ introduction aligned with observable changes in population-level health data. “It seemed like it [the impact of this medicine] was bound to show up in the data,” he explained, expressing moderate confidence that the drugs are contributing to the trend.

Strong evidence showing significant decline in obesity

Peminda Cabandugama, an endocrinologist and spokesperson for The Obesity Society, stated in a written statement to DW that “there is strong evidence showing that there is a significant decline in obesity.”

“The general opinion is that GLP-1 medications and their combinations and their increased use as well as the recent attention put on the importance of weight management have played a large and direct role in this reduction in obesity prevalence,” he added.

However, Rader emphasizes that definitive proof of causation remains elusive. While acknowledging individual weight loss success with these medications, he cautions that long-term population-level effects are uncertain. “It’s too soon to say whether it will lead to a plateau, decrease, or slower decrease in the next 20 years,” he said.

Cabandugama points to additional factors influencing current trends, including lifestyle modifications following the COVID-19 pandemic. “These trends are likely a confluence of multiple elements that include the increased use of anti-obesity medications, post-pandemic behavioral changes, increased awareness about the importance of weight management, etc.,” he explained.

Is the decline temporary?

Not all researchers share optimism about sustained improvement. The Institute of Health Metrics and Evaluation (IHME) at the University of Washington projects continued increases in obesity rates through 2035, potentially rising from 42.5% in 2022 to 46.9% in 2035.

Rader acknowledges the limitations of predictive models but warns that many are based on pre-GLP-1 drug data. In a publication in the Journal of the American Medical Association, he cautioned that models may overestimate future obesity burdens.

The IHME study authors recognize these concerns but highlight practical barriers: currently, only a small percentage of obese individuals use such medications, many discontinue treatment within a year, and weight regain often occurs after initial loss. They stress the need for more comprehensive data to evaluate long-term impacts.Billions made from weight-loss injections

To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video

Cabandugama urges continued caution despite promising trends. “While there are currently strong signs of decline, the general consensus is that it is still too early to tell whether this represents a true trend reversal.”

Consequences of decline in obesity rates would be far-reaching

Obesity has evolved beyond being viewed solely as a lifestyle issue, recognized now as a complex chronic condition influenced by biological, genetic, social, and psychological factors.

If the U.S. has indeed reached a turning point, the implications would extend far beyond individual health improvements. Weight loss among obese individuals reduces risks for numerous comorbidities, enhances mobility, increases independence, and improves quality of life.

Cabandugama anticipates early improvements in cardiometabolic markers, including blood glucose control for Type 2 diabetes, cardiovascular health, fatty liver conditions, and obstructive sleep apnea. Long-term benefits could significantly reduce healthcare system strain.

Despite encouraging data, Rader reminds us that obesity remains a major public health challenge requiring sustained attention, funding, and diverse solutions. “A turning point doesn’t mean we’re suddenly in the clear,” he emphasized. “We still have much work to do.”

This article was originally written in German.

Source link